Application of mimotopes in the treatment of autoimmune diseases will depend to a large extent upon their ability to suppress immunoreactivity, for instance by stimulating regulatory anti-inflammatory CD4+ T cells, or by directly inhibiting pathogenic cytotoxic CD8+ T cells. Here, CD8A is linked to autoimmune disease.